Fund.com, Inc., (FNDM) said today that its majority-owned subsidiary, AdvisorShares Investments, LLC, a developer and distributor of actively managed ETFs, is currently on track to have three actively managed ETFs trading on the New York Stock Exchange in April. There are currently 17 actively traded ETFs.

Fund.com CEO Gregory Webster said that AdvisorShares is one of the few firms that has approval from the Securities and Exchange Commission (technically known as exemptive relief from the provisions of the Exchange Act of 1940) to form new actively managed ETFs. Webster noted that a major advantage that AdvisorShares has is its ability to bring to market active manager strategies through an AdvisorShares ETF. An indication of the growing popularity of actively traded ETFs, Webster noted, is that Legg Mason and Eaton Vance recently joined T. Rowe Price and Goldman Sachs in asking for exemptive relief to create actively traded ETFs.

Webster said, “AdvisorShares earns its revenues from sharing in the investment advisors’ management fees by providing services to register, list and market actively managed ETFs.”

As an originator and distributor of new actively managed ETFs, Fund.com’s AdvisorShares has previously announced relationships to develop actively managed ETFs on its patent-pending ETF development platform with WCM Investment Management, Laguna, CA, in conjunction with BNY Mellon, NYC, Peritus Asset Management, Santa Barbara, CA.; and Mars Hill Partners, LLC, Colorado Springs, CO.

About Fund.com

Fund.com’s subsidiary, AdvisorShares Investments LLC, is creating actively managed ETFs to take advantage of the rapidly growing ETF business. Fund.com also is an online content provider and lead generation platform for investment funds and other financial services providers. Its objective is to engage individual investors and to match their needs with interested fund product providers. The www.fund.com website is approachable to everyday investors and serves as an educational and research resource. Fund.com also is an education provider.

About AdvisorShares

AdvisorShares is a turnkey platform for investment managers seeking to offer their investment strategy in an actively managed ETF. AdvisorShares works with experienced money managers to combine their money management expertise with the benefits the ETF structure provides. AdvisorShares provides sales, marketing and educational support to help financial advisors use AdvisorShares ETFs to help them achieve their clients’ investment goals and objectives. AdvisorShares is a leader in actively managed ETFs and is dedicated to investor education. Visit our website at www.advisorshares.com to learn more about us.

Forward-Looking Statements:
Statements in this press release regarding future performance and the potential advantages of the products and services provided by Fund.com, and any other statements about future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual performance or events to differ materially from those indicated by such forward-looking statements including the Company’s limited operating history and economic conditions generally. Additional information on potential factors that could affect results and other significant risks and uncertainties are detailed from time to time in Fund.com’s periodic reports, including Forms 10-K, 10-Q, 8-K, and other forms filed with the Securities and Exchange Commission.

Fund.com, Inc., (FNDM) announced today that it entered into a strategic alliance with Transparensee Systems, Inc.,New York City, to develop a next generation search engine for the Fund.com website to help investors find their best choices among the many thousands of mutual funds and ETFs (Exchange Traded Funds) available today. The new search engine is expected to be launched this summer.

Fund.com CEO Gregory Webster stated, “Unlike anything available today to financial investors, we believe that the new search engine will give investors more control and more choices over every search of mutual funds and ETFs. In an easy-to-use format, investors will be able to search the database for mutual funds and ETFs in real time to find specific funds that meet their criteria.”

He explained that in addition to getting only exact matches, which are typically supplied in current search engines, investors will be able to get near-perfect matches that they might not otherwise learn about. “For example, if the investor is looking for fund managers with at least ten years experience, our new search engine would also present funds with investment managers with only nine and a half years of experience who matched all the other desired criteria.”

Webster added, “Finally, investors will no longer be stopped cold with ‘no’ or few matches responses. We believe that Fund.com’s new fund search engine will make it easier for investors to find the right fund for them. We are excited about adding this sophisticated tool, which uses next generation software, to the fund.com website, thereby making it the most advanced in the industry.”

Transparensee has developed search engines using this advanced technology for four years. According to CEO Steven Lavine, the technology has proven itself on such sites as ForRent.com, which lists more than 50,000 apartments nationwide, and the restaurant search capability of Newsday’s ExploreLI.com.
Lavine said, “Using this tool, investors can make much more sophisticated searches, with more criteria and still find a good match.”

About Fund.com

Fund.com is an online content provider and lead generation platform for investment funds and other financial services providers. Its objective is to engage individual investors and to match their needs with interested fund product providers. The www.fund.com website is approachable to everyday investors and serves as an educational and research resource. Fund.com also is an education provider. Fund.com’s subsidiary, AdvisorShares Investments LLC, is creating actively managed ETFs, to take advantage of the rapidly growing ETF business.

Forward-Looking Statements:

Statements in this press release regarding future performance and the potential advantages of the products and services provided by Fund.com, and any other statements about future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual performance or events to differ materially from those indicated by such forward-looking statements including the Company’s limited operating history and economic conditions generally. Additional information on potential factors that could affect results and other significant risks and uncertainties are detailed from time to time in Fund.com’s periodic reports, including Forms 10-K, 10-Q, 8-K, and other forms filed with the Securities and Exchange Commission.

Provectus Pharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has received gross proceeds of approximately $7.5 million in a private placement offering to institutional and accredited investors. In connection with the closing, the Company issued approximately 10.0 million shares of its convertible preferred stock and warrants to purchase approximately 5.0 million shares of its common stock at an exercise price of $1.00 per share. The Company expects to close on additional gross proceeds of approximately $450,000 on or before March 15. The shares issued to the investors and the shares underlying the warrants have not been and will not be registered under the Securities Act of 1933, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release shall not be deemed an offer to sell or a solicitation of an offer to buy any securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The Company intends to use the proceeds of the private placement for working capital purposes. Peter Culpepper, the Company’s CFO and COO said, “With the closing of this offering, Provectus has strengthened its operational activities and expanded its shareholder base to include new individual and institutional investors. We believe we have now raised enough capital to fully finance existing clinical trials through to completion, and do not anticipate the need for any further capital in order to bring our existing metastatic melanoma therapy to completion of clinical trials. As our discussions with the FDA regarding an accelerated path continues, we wanted to make sure we are prepared to move ahead with our development activities if a Phase 3 study is needed. We intend to continue to work with the FDA and other authorities to rapidly register our groundbreaking therapies, so that we can serve the many patients who need them.”

He continued, “Provectus also believes that it is well positioned to execute on its growth strategy by developing its oncology and dermatology therapies through clinical trials, strategic partnerships and licensing agreements. We remain committed to further develop our dermatology therapies with an industry partner, and expect to continue to develop our other oncology indications.”

Maxim Group LLC served as the Company’s exclusive placement agent for the transaction.
About Provectus Pharmaceuticals, Inc. (www.pvct.com)

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its lead oncology agent, PV-10, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic liver cancer. The Company has received orphan drug designation from the FDA for its melanoma indication. Its lead dermatological drug, PH-10, also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed enrollment in three of its Phase 2 trials — PV-10 as a therapy for metastatic melanoma, and PH-10 as a topical treatment for atopic dermatitis and for psoriasis. It has also recently initiated a Phase 1 trial for PV-10 for liver cancer. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company’s website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

CoroWare Technologies, a subsidiary of CoroWare, Inc. (COWI), announced today it has added a new accessory to its growing line of robotics products.

A compact and affordable laser range finder is the latest addition to the company’s online product catalog. The laser range finder can be purchased individually or as an option on the CoroBot and Explorer robots. Purchased as a robot option, the laser comes fully installed with drivers pre-loaded on the robot’s computer. A 10Hz scanning frequency and range of over 18 ft. significantly increases the robots’ sensing power.

“Recent advances in laser range finders, including a reduction in their size and power requirements, along with declining cost, now makes the technology appropriate for smaller robotics systems,” said Dan Kara, robotics industry analyst and President of Robotics Trends. “The addition of a laser range finder option for CoroWare’s CoroBot and Explorer platforms greatly increases the number and range of applications the robots are suited for.”

CoroBots and Explorers equipped with laser range finders can leverage established functions such as Monte Carlo localization and Simultaneous Localization and Mapping (SLAM). This makes CoroWare’s robots even more suitable for inspection tasks, remote presence tasks, and academic research, operating both singly and in swarms.

This new accessory is the latest in a series of growth activities for CoroWare’s Robotics and Automation group. In February, the company announced a differential-drive robot base option, more powerful motors and robust sensing mechanisms.

“We continuously evaluate customer feedback and actively engage in R&D activities to further expand our robotics product line,” said Lloyd Spencer, CEO of CoroWare, Inc. “Keeping close watch on customer demand helped CoroWare’s Robotics and Automation group increase product sales by more than 11% in 2009 during a global recession.”

Customers looking for capable, expandable and affordable mobile robotic products can visit http://robotics.coroware.com/products for more information on pricing and specifications.

About CoroWare

Headquartered in Redmond, Washington, CoroWare is a solutions integrator with expertise in mobile robotics and personal telepresence. For more information on CoroWare’s products and services, please visit www.coroware.com. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company’s actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company’s plans or expectations.

Provectus Pharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala, Principal Investigator for Provectus’ Phase 2 PV-10 trial site at St. Luke’s Hospital & Health Network in Bethlehem, PA, will present an update on the Company’s ongoing Phase 2 trial of PV-10 for metastatic melanoma at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, in New York City.

Dr. Agarwala’s presentation, “Chemoablation in Melanoma: An Update,” will be presented during the session entitled “Unique Approaches to Melanoma Therapy.”

Craig Dees, Ph.D., CEO of Provectus said, “We look forward to Dr. Agarwala’s update to the medical community on the clinical progress that has been made with PV-10 for metastatic melanoma since last year’s conference. From our research, we believe that PV-10 is proving to have great promise as a safe and effective therapeutic for this devastating cancer that affects so many people each year, and for which there are few viable treatments. Dr. Agarwala’s presentation should highlight many of the reasons we are excited about the data from PV-10’s clinical trials.”

According to the American Cancer Society, there were over 68,000 new cases of melanoma, and over 8,600 deaths in the U.S. in 2009. Further, the World Health Organization has estimated that 48,000 patients globally died from melanoma in 2008.

About The Seventh International Symposium on Melanoma and Other Cutaneous Malignancies

The Seventh International Symposium on Melanoma and Other Cutaneous Malignancies will continue a strong history and provide participants with a comprehensive overview of state-of-the-art care of patients with these diseases. Specific topics to be highlighted at this symposium include current risk assessment factors and diagnostic technologies, new prognostic and predictive biomarkers with clinical potential for individualizing treatment, and promising emerging systemic immunotherapies, targeted therapies, and regional therapies for advanced melanoma and other cutaneous malignancies. These topics and the implications for practice will be presented by leading experts in the treatment of these different tumor types. This interactive symposium will also cover practical issues concerning surgical management and adjuvant therapy for these patients. These concepts and practical diagnostic issues will be further reinforced through 2 interactive case-based discussion sessions with the faculty to provide expert insights into their application in practice. Throughout the symposium, participants will also learn about currently accruing high-priority trials and the relevant patient eligibility criteria to enhance enrollment into trials evaluating novel therapeutic regimens in the adjuvant and advanced disease settings for melanoma and other cutaneous malignancies.

About Provectus Pharmaceuticals, Inc. (www.pvct.com)

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its lead oncology agent, PV-10, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic liver cancer. The Company has received orphan drug designation from the FDA for its melanoma indication. Its lead dermatological drug, PH-10, also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed enrollment in three of its Phase 2 trials — PV-10 as a therapy for metastatic melanoma, and PH-10 as a topical treatment for atopic dermatitis and for psoriasis. It has also recently initiated a Phase 1 trial for PV-10 for liver cancer. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company’s website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

One of the leading networks of forum communities on the Internet, CrowdGather (CRWG), today announced that it has acquired the domain names and site related to a long-standing community of Nintendo fans at www.nsider2.com. According to Wikipedia, Nsider2 was one of several fan communities that launched after Nintendo decided to close its Nsider fan forums during a site overhaul in September, 2007. The Nintendo site reopened the forums in December, 2007, but with a focus on technical support for gamers.

Nsider2 is a leading gaming site with over 13,000 registered members and traffic of over 2 million monthly page views according to Google analytics.

“We are pleased to add this robust fan community to our gaming vertical,” said Sanjay Sabnani, CrowdGather’s Chairman and CEO. “We believe forums are a big part of Internet history and Nsider2 is no exception. Formed by Nintendo gaming fans for other fans, the community is entering its third year of existence and still going strong. We welcome them to the CrowdGather family”.

About CrowdGather, Inc.

With its growing portfolio of special interest forums and enthusiast message board communities, CrowdGather (www.crowdgather.com) has created a centralized network to benefit forum members, forum owners and forum advertisers. CrowdGather provides a highly interactive and informational social network for members, a management and revenue-sharing resource for third-party forum owners, and a largely untapped advertising network for marketers worldwide.

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events and the Company’s growth and business strategy. Words such as “expects”, “will”, “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, and variations on such words and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, changes in the Company’s business; competitive factors in the market(s) in which the Company operates; risks associated with operations outside the United States; and other factors listed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Ingen Technologies, Inc. (IGNT.PK), which has developed and patented an innovative cannula that monitors oxygen flow, stands at a key reflex point in unlocking value for shareholders. Its products are obtaining final certification, contracts are in place which has lined up distributors, financials are being cleaned up, and management is poised to rapidly expand sales and drive value for shareholders.

A Growing $500 Million per Year Industry

With more than 20 million patients in the USA and 600 million patients worldwide, using oxygen at home and millions more in hospitals, cannulas represent a $500 million per year market segment in the $4 billion per year respiratory industry. Meanwhile, the market is rapidly expanding both in the U.S. and abroad as an aging population increasingly requires oxygen to combat the #4 leading cause of death in the USA and #1 leading cause of death in Asia and Europe.

Chronic obstructive pulmonary disease – or COPD for short – represents a group of lung diseases that block airflow and make it increasingly difficult to breathe. The illness is a leading cause of death worldwide, mostly caused by long-term smoking. The key treatments are oxygen tanks with cannulas that provide a higher concentration of oxygen with each breath.

Currently, Medicare provides approximately $189 in reimbursements for oxygen tanks, which is noticeably down from the $500 per month before the global economic crisis. The cutbacks have forced many in-home care providers and patients to seek a low-cost alternative, but it turns out that Ingen’s technologies “Oxyview Cannula” offers the best long-term cost savings and consumer benefit.

Cannulas that Cut Costs and Improve Care

Ingen Technologies has developed an innovative new cannula that it calls Oxyview. Unlike traditional cannulas, Oxyview monitors oxygen flow in order to give patients peace-of-mind and provide cost-savings to in-home care companies by reducing needless support calls and improving patient care.

“I believe this device will eliminate most of the after-hour calls we get and thus not have to send someone out to check the machine,” said Deena Neal of Professional Oxygen Supply, Inc. “Everyone in this industry is looking for ways to reduce costs and I think [Ingen’s Oxyview] will be a great way to help with that.”

Many other customers enjoy using the device in order to ensure patient safety as well. Dr. Gary Call, Chief Medical Officer of Bingham Memorial Hospital in Blackfoot, Idaho, was one of these people who purchased Ingen’s Oxyview cannulas to ensure that every one of the nursing home residents has oxygen flow after experiencing a problem with an empty tank earlier.

“For less money than [our patient’s] trip to the emergency room cost, we bought enough Oxyviews to ensure every one of the nursing home residents has flow in their cannulas,” said Dr. Gary Call. “[Moreover], no longer does our staff have to lean down and lift the tank out of its bracket, let it find a balance point, before determining whether or not oxygen is available.”

Poised to Break Into Key Markets

Ingen Technologies faces few hurdles before breaking into the market in a big way. These hurdles include obtaining key licenses and certifications, as well as identifying a distributor to bring Oxyview to larger medical institutions. Fortunately, the company is at a point where it is poised to surpass many of these issues in the near-term and is in the process of doing so.

On January 28th, Ingen announced that it had officially signed a contract with Texas-based KGMA Business solutions for pursuing U.S. Government contracts. The firm had prepared and submitted the GSA application for Ingen on September 22, 2009, which after completion of approval, opens the door to more than 300 VA hospitals in the U.S.

On February 8th, Ingen announced that it passed Stage-I of its ISO 13485 Certification audit that is necessary to open international sales channels where it already has a substantial backlog and distribution partners lined up. Completion of the final Stage-II audit is set for March 2010 and meets its 2010 projections of $11 million in sales.

Getting the Financials in Order

On November 4, 2009, Ingen engaged CDM Capital, LLC to provide interim financial consulting services and assist the company with restating, if necessary, its financials in 2007 and 2008, as well as working to prepare and submit missing SEC reports and preparing reports and financial statements for posting on PinkSheets.com, according to an 8-K filing with the SEC.

Ingen expects to become a fully reporting company again at the end of the fiscal year on May 30, 2010, while it is already in full compliance with PinkSheets.com reporting. Investors can find its latest 10-Q filing on PinkSheets.com or by clicking on this link.

A Commitment to Shareholders

Ingen also remains very committed to their shareholder base, as evidenced by their recent stock repurchase program. Reducing the number of outstanding shares will help increase the company’s earnings per share (EPS) and enable it to reach levels acceptable for an up-listing in the future when it fulfills its SEC reporting requirements.

According to a recent press release, “We have strong investment commitments to assist the company with a stock buyback program. In order to comply with the forebearance agreement with the NIR Group, we will seek majority vote from our shareholders to increase the authorized so we can pay off the balance of the note owed to various funds managed by NIR Group and move forward with the share buyback program.”

Currently, Ingen trades with a market capitalization of about $5.4 million with approximately 3.4 billion shares outstanding. However, a jump in sales and net income could quickly ramp up these numbers, with its high profit margins, low overhead, and growing distribution channels.

Long-term Plans Going Forward

Ingen remains uniquely position in the $400-500 million per year market for oxygen cannulas as the only provider of smart cannulas. With four patents issued and six pending, it has an exclusive presence in the market that could make it a potential acquisition target for a medical device maker looking for an inroad into in-home oxygen providers.

“We have a strong commitment to our shareholders and to the success of this company,” said Chairman and CEO Scott Sand. “There is no doubt that our medical products are now on the way to creating the revenues and recognition that they deserve in the marketplace … The heart of our success lies within the risks we have taken and our belief in these new medical products and success for this company.”

Ingen Technologies, Inc. (IGNT), a leading manufacturer of respiratory medical devices, recently announced today that the company was granted approval of the Stage-II audit conducted by BSI America, Inc. on March 2, 2010, and the Auditor has recommended Ingen for ISO 13485 certification.

Accordingly, the auditor had recommended that the scope of activities detailed in his report meet registration requirements and that the recommendation would be independently verified within BSI. Upon final verification, the ISO 13485 certificate of registration will be issued. Further, the company will meet CE Mark requirements for Europe. Customarily, the company expects to receive its certificate in 4-5 weeks.

ISO 13485:2003 specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer requirements and regulatory requirements applicable to medical devices and related services in order to market and sell their product in various countries.

The primary objective of ISO 13485:2003 is to facilitate harmonized medical device regulatory requirements for quality management systems. As a result, it includes some particular requirements for medical devices and excludes some of the requirements of ISO 9001 that are not appropriate as regulatory requirements. Because of these exclusions, organizations whose quality management systems conform to this International Standard cannot claim conformity to ISO 9001 unless their quality management systems conform to all the requirements of ISO 9001.

All requirements of ISO 13485:2003 are specific to organizations providing medical devices, regardless of the type or size of the organization.

“We believe that this ISO certification is a major part of our critical path to generating substantial revenues for this company. With initial pending back-orders in Europe, Asia and Australia, we expect to see $11M in sales in 2010. In addition, our General Services Administration (GSA) application is expected to be approved this month, and KGMA Business Solutions has already begun working on a distribution program.” Stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

http://www.bsiamerica.com/

http://www.emergogroup.com/services-by-region/usa

http://www.ingen-tech.com/

http://www.kgmasolutions.com/

http://www.smartnasalcannula.com/

http://www.ingenpulseoximeter.com/

http://www.oxyviewnasalcannula.com/default.html

About Ingen:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and a successful registration with the Food & Drug Administration. The company has domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the Oxyview Nasal Cannula was introduced as the world’s first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced the Oxyview Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

The Investor-Based video makes the business case by showing how parents today are faced with a giant challenge—keeping their children safe on the internet from predators, pornography, and malicious online communication. This video will not only introduce the many facets of our cutting-edge technology, including our Secure-Chat, Secure-Search, Secure-Browse, and Secure-Email, but also provides potential investors a look at our Corporate Vision and the potential profits thereof. With a thorough explanation of our marketing options, distribution outlets, and advertising sources, along with a detailed description of the scope of our market, this video hammers home this unique investment opportunity.

Richard J. Lewis III, CEO of CITC, stated “IDEAS has really helped us hit the mark with this Investor-Based Video … I think together we have created a top-notch, informative vehicle for serious investors to really see and understand the true long-term potential that a partnership with CITC has to offer.”

Daniel Schoenthal, one of CITC’s technical gurus, states “many competitive products that claim to protect children are rife with shortcomings. With overzealous filtering of content, inadequate parental controls, and “one size fits all” rules for children regardless of age, treating a 4-year-old the same as a 14-year-old, the current security products are truly lacking. This is especially exasperating because many of the filtering controls are capable of being easily hacked, even by an 8-year-old!”

The CITC Team directly addresses these failings, providing parents with an award winning solution with its patent pending Wizard Lock Security™. The Parental Control market is ripe for a solution that truly works. According to Mr. Lewis, “it’s a Billion Dollar market with a whopping 76% forecasted growth rate. With relatively low penetration, the marketplace has been stuck in neutral waiting for a solution that is effective, affordable, and user-friendly…and the truly exciting thing is…the CITC Team has that solution.”

For more information, or to view the Investor-Based video, please visit: www.kidwideweb.net and request a password or contact Richard J. Lewis III @ 916-631-1988. Or you can email us at info@kidwideweb.net. For additional information, you can also visit www.thechildrensinternetinc.com.

Forward-Looking Statements:
This press release may be deemed to contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements are made as of today’s date and we do not undertake any obligation to update forward-looking statements. You can identify such statements by our use of such words as “should,” “expect,” “will,” “intends,” and similar words and phrases which denote future events and which may depend on the future performance of the Company. Specifically, these include statements as to future product releases, the implementation of strategic initiatives and the ownership in TCI upon completion of the transaction and whether or not the transaction will be consummated. Our assumptions underlying these statements are also “forward-looking” statements. Forward-looking statements are based on information and assumptions that are dynamic in nature and subject to rapid and sometimes abrupt changes. Our forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those stated or implied by the statements. Our forward-looking statements are also subject to important risks and uncertainties detailed in our latest reports filed with the SEC and available on its website at www.sec.gov.

Provectus Pharmaceuticals, Inc. (PVCT), a biotechnology company focused on developing cancer and psoriasis treatments using the Rose Bengal compound, found in recent Phase I and II studies that its lead PV-10 compound demonstrates a unique “bystander effect” that results in improvements in other melanoma tumors that were not directly treated.

The occurrence suggests that PV-10 is able to not only safely and effectively treat cancerous tumors, but also jumpstart the body’s own immune system to combat cancer in adjacent regions that were not directly treated. As a result, PV-10 could be even more effective than first envisioned when it comes to completely eradicating cancer from a patient.

PV-10 studies have shown that thick, oily red dye exhibits preferential uptake into lysosomes of cancer cells but it is excluded from normal cells, resulting in selective necrosis in multiple melanoma lines. Essentially, this means that the Rose Bengal compound is able to selectively kill cancer cells without damaging the surrounding cells.

Meanwhile, scientists also noticed that bystander lesions that were not directly treated also improved, in about 50% of cases, within the study follow-up. The company believes that the exposure of tumor antigens in context from the cells that are destroyed is what promotes the activity, but further study is necessary to show more completely how it works.

Over the past 50+ years, scientists have also clearly demonstrated that the compound is not metabolized in the body. Rather, it is excreted rapidly and has minimal toxicity in healthy tissues. These attributes have helped PV-10 conduct current compassionate use studies under the auspices of the FDA and could help fast-track PV-10 further through any remaining clinical trial.

In the end, Provectus’ PV-10 candidate is showing great promise in not only treating tumors, but also jumpstarting the body’s own immune system to fight surrounding cancer cells. As a result, scientists are increasingly confident in the drug’s ability to one-day make a lasting impact in the world’s fight against cancer.

Click Here to Learn More about Provectus Pharmaceuticals (PVCT)